Milestone Scientific Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Milestone Scientific wird ein Gewinn- und Umsatzwachstum von 33.8% bzw. 12.9% pro Jahr prognostiziert, während der Gewinn pro Aktie um 37.1% pro Jahr wachsen soll.

Wichtige Informationen

33.8%

Wachstumsrate der Gewinne

37.1%

EPS-Wachstumsrate

Medical Equipment Gewinnwachstum	16.7%
Wachstumsrate der Einnahmen	12.9%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	16 May 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Did You Miss Milestone Scientific's (NYSEMKT:MLSS) Whopping 317% Share Price Gain?

Feb 23

Here's What Milestone Scientific Inc.'s (NYSEMKT:MLSS) Shareholder Ownership Structure Looks Like

Dec 15

Earnings Update: Here's Why Analysts Just Lifted Their Milestone Scientific Inc. (NYSEMKT:MLSS) Price Target To US$4.00

Nov 19

Gewinn- und Umsatzwachstumsprognosen

NYSEAM:MLSS - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2025	12	-4	N/A	N/A	1
12/31/2024	10	-5	N/A	N/A	1
3/31/2024	9	-7	-5	-5	N/A
12/31/2023	10	-7	-5	-5	N/A
9/30/2023	10	-7	-5	-5	N/A
6/30/2023	10	-7	-5	-5	N/A
3/31/2023	9	-8	-7	-7	N/A
12/31/2022	9	-9	-6	-6	N/A
9/30/2022	9	-8	-5	-5	N/A
6/30/2022	9	-8	-6	-6	N/A
3/31/2022	10	-8	-5	-5	N/A
12/31/2021	10	-7	-4	-4	N/A
9/30/2021	10	-7	-4	-4	N/A
6/30/2021	9	-6	-5	-5	N/A
3/31/2021	7	-7	-7	-7	N/A
12/31/2020	5	-7	-7	-7	N/A
9/30/2020	6	-9	-7	-7	N/A
6/30/2020	6	-10	-5	-5	N/A
3/31/2020	8	-8	-3	-3	N/A
12/31/2019	8	-8	-2	-2	N/A
9/30/2019	10	-4	-1	-1	N/A
6/30/2019	10	-6	-1	-1	N/A
3/31/2019	10	-6	-1	-1	N/A
12/31/2018	10	-7	-2	-2	N/A
9/30/2018	8	-9	-2	-2	N/A
6/30/2018	9	-6	-2	-2	N/A
3/31/2018	9	-7	-1	-1	N/A
12/31/2017	11	-5	N/A	-1	N/A
9/30/2017	11	-5	N/A	-3	N/A
6/30/2017	11	-6	N/A	-3	N/A
3/31/2017	11	-6	N/A	-5	N/A
12/31/2016	10	-6	N/A	-5	N/A
9/30/2016	11	-6	N/A	-3	N/A
6/30/2016	11	-5	N/A	-4	N/A
3/31/2016	10	-6	N/A	-4	N/A
12/31/2015	9	-5	N/A	-3	N/A
9/30/2015	10	-5	N/A	-3	N/A
6/30/2015	10	-4	N/A	-2	N/A
3/31/2015	10	-2	N/A	-1	N/A
12/31/2014	10	-2	N/A	0	N/A
9/30/2014	10	1	N/A	1	N/A
6/30/2014	10	1	N/A	1	N/A
3/31/2014	10	2	N/A	2	N/A
12/31/2013	10	1	N/A	1	N/A
9/30/2013	9	0	N/A	0	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: MLSS wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: MLSS wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: MLSS wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: MLSSDie Einnahmen des Unternehmens (12.9% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.7% pro Jahr).

Hohe Wachstumseinnahmen: MLSSDie Einnahmen des Unternehmens (12.9% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von MLSS in 3 Jahren voraussichtlich hoch sein wird

Milestone Scientific Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus revenue estimates decrease by 10%

Consensus revenue estimates decrease by 13%

Consensus EPS estimates fall by 29%, revenue upgraded

Consensus estimates of losses per share improve by 12%

Consensus forecasts updated

Price target decreased to US$4.00

Recent updates

Milestone Scientific Receives Regulatory Approval to Market Compuflo Epidural System in Brazil

Milestone Scientific Inc., Annual General Meeting, Jul 16, 2024

First quarter 2024 earnings: EPS in line with expectations, revenues disappoint

Consensus revenue estimates decrease by 10%

Full year 2023 earnings: EPS and revenues miss analyst expectations

Milestone Scientific Inc. has completed a Follow-on Equity Offering in the amount of $3.00195 million.

New minor risk - Shareholder dilution

Milestone Scientific Inc. has filed a Follow-on Equity Offering.

Consensus revenue estimates decrease by 13%

New major risk - Financial position

Third quarter 2023 earnings: EPS in line with expectations, revenues disappoint

Director notifies of intention to sell stock

Less than half of directors are independent

Milestone Scientific Inc. Appoints Didier Demesmin to Board of Directors

Milestone Scientific Inc. Announces Resignation of Peter J. Milligan as Chief Financial Officer, Effective September 1, 2023

Consensus EPS estimates fall by 29%, revenue upgraded

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New minor risk - Share price stability

Consensus estimates of losses per share improve by 12%

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Milestone Scientific Inc. Announces the Appointment of Peter Milligan as the Chief Financial Officer

Milestone Scientific Inc. Announces Board Changes

Milestone Scientific Inc. Appoints Neal Goldman as Chairman of the Board of Directors

Leonard M. Schiller Tenders His Resignation to Milestone Scientific Inc. as A Director

Insufficient new directors

Consensus forecasts updated

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Insufficient new directors

Milestone Scientific Inc. Reports Commencement of Sales of its CompuFlo(R) Epidural Instrument Disposables at a Leading Veterinary and Academic Institution

First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Insufficient new directors

Milestone Scientific Inc., Annual General Meeting, Jun 13, 2022

Price target decreased to US$4.00

Price target decreased to US$4.00

Founder notifies of intention to sell stock

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Founder notifies of intention to sell stock

Milestone Scientific Inc. Provides Revenue Guidance for the Fourth Quarter and Year Ended December 31, 2021

Founder exercised options to buy US$268k worth of stock.

Third quarter 2021 earnings released: US$0.029 loss per share (vs US$0.023 loss in 3Q 2020)

Founder exercised options to buy US$417k worth of stock.

Independent Chairman of the Board notifies of intention to sell stock

Independent Chairman of the Board recently sold US$86k worth of stock

Consensus EPS estimates fall to -US$0.11

Second quarter 2021 earnings released: US$0.039 loss per share (vs US$0.056 loss in 2Q 2020)

Chief Financial Officer Scott Kahn has left the company

Milestone Scientific Inc.(NYSEAM:MLSS) dropped from Russell 3000E Value Index

Consensus forecasts updated

First quarter 2021 earnings released: US$0.015 loss per share (vs US$0.032 loss in 1Q 2020)

Consensus revenue estimates increase to US$10.3m

Full year 2020 earnings released: US$0.12 loss per share (vs US$0.17 loss in FY 2019)

Milestone Scientific Receives Notice of Allowance for European Patent Related to Combination of Nerve Stimulation and Dps Dynamic Pressure Sensing Technology® to Optimize Needle Tip Location in Ultrasound-Guided Pnb Procedures

Milestone Scientific Inc. Commences Sales of CompuFlo® / CathCheck™ Disposables to the Nationally Recognized Medical University of South Carolina

New 90-day high: US$4.13

Did You Miss Milestone Scientific's (NYSEMKT:MLSS) Whopping 317% Share Price Gain?

Independent Chairman of the Board notifies of intention to sell stock

Analysts update estimates

Independent Chairman of the Board recently sold US$169k worth of stock

Milestone Scientific Inc. Adds Three Additional Premier Distributors Providing Robust U.S. Coverage and A New Distributor in Canada for the Company’S Dental Instrument

Milestone Scientific Inc. Signs Two Additional Distribution Agreements with Atlanta Dental and Nashville Dental for its Wand Single Tooth Anesthesia System

New 90-day high: US$3.48

Director recently sold US$215k worth of stock

Milestone Scientific Inc. Receives Notice of Allowance for U.S Patent Related to Compuflo® Disposables

New 90-day high: US$2.90

Milestone Scientific Inc. Announces It Has Begun Implementing Three-Year Strategy to Expand the World-Wide Global Dental Market

Milestone Scientific Inc. Announces Agreement with Bitmedical AG to Distribute the CompuFlo® Epidural Instrument Across Austria and Switzerland

Milestone Scientific Inc. Raises Revenue Guidance for Fourth Quarter 2020

Founder exercised options to buy US$183k worth of stock.